ArticleCureus2025
Mineral Bone Disease Prevalence and Biochemical Profile in Chronic Kidney Disease Patients Undergoing Hemodialysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Mineral bone disease (MBD) is a common complication in patients with stage 5 chronic kidney disease (CKD) undergoing maintenance hemodialysis. This study aimed to evaluate the prevalence and biochemical profiles of MBD in this patient population in India. Methods This cross-sectional study was conducted at a tertiary hospital in southern India over a period from June 2020 to November 2021 with 152 patients with stage 5 chronic kidney disease (CKD) undergoing maintenance hemodialysis for at least three months. Blood samples were collected prior to routine dialysis sessions to assess levels of calcium, phosphate, intact parathyroid hormone (iPTH), 25-hydroxy vitamin D, bone-specific alkaline phosphatase (BSAP), and total alkaline phosphatase (ALP). Patients were categorized based on their iPTH levels into four distinct groups: < 2 times, 2 to 5 times, 5 to 9 times, and > 9 times the upper normal limit (which is 65 pg/ml). Results Low-turnover MBD (iPTH < 2 times the upper limit) was predominant with 66 (43.4%) patients, whereas 17 (11.18%) patients had high-turnover MBD (iPTH > 9 times the upper limit). Hypocalcemia and hypercalcemia affected 42 (27.6%) and 14 (9.2%) patients, respectively. Vitamin D insufficiency was found in 88(57.9%) patients, and deficiency was found in 18 (11.8%) patients. BSAP levels were predominantly high (≥27 IU/L) across all iPTH groups, with no statistically significant variation. In contrast, total alkaline phosphatase (ALP) levels showed a significant positive correlation with iPTH levels (p=0.001), with higher iPTH levels associated with a greater proportion of ALP values > 110 IU/L. These findings underscore the high prevalence of MBD in Indian patients with CKD on hemodialysis, emphasizing the need for biochemical monitoring to facilitate early detection and optimal management for improved outcomes. Conclusion The high prevalence of MBD in Indian patients with CKD on hemodialysis underscores the need for regular biochemical monitoring. Early detection and optimal management strategies are essential to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.